Build countermeasures against infectious diseases using “high sensitivity and high speed” biosensor technology

New biosensor A: possible substitution of antibody
Biosensor A is a new examination technology expected to be utilized to detect viruses and in-vivo proteins. From the features such as “high sensitivity and specificity”, “easy to maintain”, it is said to be superior to antibody testing which is the de facto standard of protein detection test. However, because it is necessary to repeat processes such as “artificial synthesis”, “integration test” and “evaluation” in order to discover a biosensor A specific to a certain protein, it takes 2- 3 years to find one specific biosensor . Hence, this lengthy development period has been an obstacle to make this available for wide use.

Accelerated development of biosensor A using IT technology
Under such circumstances, utilizing its big data analysis technologies, the company established the technology to recognize the pattern of the biosensor A, and to discover the protein-specific biosensor A in several weeks to a few months. Initially, they were considering using this for a certain infectious disease examination however they were not convinced of the business potentials and therefore was not able to make a decision regarding the direction they should take. e-solutions then supported them in market selection and business development.

Business development for “Infectious Disease Control Infrastructure”
Through interviews with experts, we selected three promising markets for biosensor A technology. As a result of evaluating the marketability for each, we made a suggestion that they enter the examination market for four infectious diseases such as influenza. We also compiled a business model where they utilize their IT technologies to discover infectious disease at early stage and lead to the development of “Infectious Disease Control Infrastructure”.
Following our suggestion, utilizing our business network, we selected potential strategic partners that are necessary for the commercialization. We also made recommendations to the government and ministries aiming to build momentum.